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T ype 2 diabetes is characterized by both insulin resistance and a defect in insulin secretion, which is inadequate to compensate for insulin resistance leading to hyperglycemia. Hyperglycemia, in turn, exerts deleterious effects on b-cells, known as "b-cell glucotoxicity" (1) .
C-jun N-terminal kinase (JNK), a stress-activated kinase (2) , is activated in diabetes (3) . JNK mediates obesityinduced insulin resistance by interfering with insulin signaling (4) (5) (6) . Inhibition of JNK ameliorates glucose tolerance in animal models of type 2 diabetes by improving insulin sensitivity (5, 6) and insulin biosynthesis (6) .
Numerous studies, including ours (7) , have shown that oxidative stress, which is present in the diabetic state (1) , plays a role in glucose-induced b-cell dysfunction both in vitro (8) (9) (10) (11) and in vivo (7, 12, 13) . Oxidative stress activates JNK in various tissues, including pancreatic islets (14) . Oxidative stress-induced activation of JNK impairs insulin gene transcription by inducing the nucleocytoplasmic translocation of Pdx-1 (15) . JNK can also be activated by endoplasmic reticulum (ER) stress (14) , and we have shown that ER stress plays a role in b-cell dysfunction induced by glucose in vivo (16) .
Inhibition of JNK prevents glucose-induced b-cell dysfunction and apoptosis in human islets and in a b-cell line (17) . Islets overexpressing dominant negative JNK had greater insulin gene expression than control islets after transplantation in streptozotocin-induced diabetic nude mice (18) . However, no other information is available about the role of JNK in vivo, and in particular, it is not known whether JNK inhibition protects b cells from hyperglycemia per se.
The objective of the current study is to investigate the causal role of JNK activation on b-cell dysfunction in vivo in a selective model of hyperglycemia (i.e., in the absence of other metabolite/hormone changes that are present in diabetes). The effect of prolonged hyperglycemia per se with or without JNK inhibition on b-cell function was evaluated both in isolated islets and in vivo using hyperglycemic clamps. The effect of JNK inhibition was investigated by using (i) the JNK inhibitor SP600125 (SP) or (ii) JNK-1-null mice. SP is a reversible ATPcompetitive JNK inhibitor that inhibits all three isoforms (JNK-1, JNK-2, and JNK-3) with equal potency (19) . JNK-1-null mice were also used because JNK-1 is the main isoform associated with type 2 diabetes (5).
Materials and Methods

Animals
All procedures were approved by the Animal Care Committee of the University of Toronto. Eight-to ten-week-old female Wistar rats (Charles River, Senneville, QC, Canada) received vessel cannulation as previously described (20) . The jugular cannula served for infusion, the carotid cannula for blood sampling. A jugular vein of 10-to 12-week-old male JNK-1-null mice (Jackson Laboratory, Bar Harbor, ME) and their littermate wild-type (WT) controls (on C57Bl6/J background) was cannulated as described in Koulajian et al. (21) . Sampling in mice was through the tail vein.
Infusions
After 2 to 3 days postsurgery recovery, rats were randomized and infused intravenously for 48 hours with (i) saline (SAL); (ii) a variable infusion of 37.5% glucose to achieve and maintain hyperglycemia at~20 to 22 mM [high glucose (HG)], as in our previous studies (7); (iii) glucose + the JNK inhibitor SP (Sigma, St. Louis, MO) (HG + SP); and (iv) SP alone without glucose infusion (SP). Plasma glucose was maintained at 20 mM by adjusting the rate of glucose infusion according to frequent (every 2-to 3-hour) glycemic determinations. SP dissolved in 20% (2-hydroxypropyl)-b cyclodextrin (Sigma), pH 7.4, was given at 0.05 mmol$kg 21 
$min
21 , a dose derived from previous in vivo studies (22) . Although newer JNK inhibitors have been developed that are currently being evaluated, SP is still the most widely used JNK inhibitor (23) .
In mice, we used a milder but more prolonged protocol of hyperglycemia, as mice do not tolerate the glucose infusion required to achieve hyperglycemia at 22 mM for 48 hours, because of overhydration due to their small size. After 3 to 4 days postsurgery recovery, JNK-1-null mice [knockout (KO)] and WT littermate controls were infused for 96 hours with either (i) SAL (KO SAL; WT SAL) or (ii) a variable infusion of 50% glucose to elevate plasma glucose to ;13 mM (KO HG; WT HG). WT mice were also infused with (iii) glucose + SP (WT HG + SP) or (iv) SP alone (WT SP). The same dose of SP as in rats was used.
Determinations in islets ex vivo
After a 48-hour (rats) or 96-hour (mice) infusion, islets were isolated using previously described methods (24) . Thereafter, glucose-stimulated insulin secretion was evaluated as in our previous studies (21) . Western blots were performed as previously described (25) with primary antibodies for phospho-cjun (Ser73) (catalog no. 9164; Cell Signaling Technology; RRID: AB 330892) (26) , total c-jun (catalog no. 9165; Cell Signaling Technology; RRID: AB 230165) (27) , and actin (catalog no. sc-1615; Santa Cruz Biotechnology; RRID: AB 630835) (28) . Total and mitochondrial superoxide were measured as previously described (7) . Islet RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) for real-time RT-PCR using the TaqMan Gene Expression System (Applied Biosystems, Carlsbad, CA) (29) . Primers for mouse insulin 2 (mmol/l00731595_gH) and Pdx-1 (mmol/l00435565_m1) were obtained from Applied Biosystems.
Studies in vivo
In rats, a two-step hyperglycemic clamp was used as in our previous study (7) . At the end of 48 hours, glucose infusion in HG and HG + SP groups was decreased to~5 mL/min for 75 minutes to achieve basal glucose without hypoglycemia. At time 0, an infusion of 37.5% glucose was started. Plasma glucose was maintained at ;13 mM by adjusting the rate of glucose infusion according to frequent (5-to 10-minute) glycemic determinations. At 120 minutes, the glucose infusion was again raised to~22 mM until the end of the experiment (240 minutes). Samples for insulin and C-peptide were taken at regular intervals. Plasma glucose was measured using a Beckman Analyzer II (Beckman Coulter, Fullerton, CA).
In mice, a one-step hyperglycemic clamp was performed. At the end of 96 hours, glucose infusion was stopped for 90 minutes to bring plasma glucose back to basal levels. At time 0, an infusion of 37.5% glucose was started. Plasma glucose was maintained at~20 mM by adjusting the rate of glucose infusion according to frequent (every 10-minute) glycemic determinations on a Hemocue analyzer II (HemoCue, Lake Forest, CA). Samples for insulin and C-peptide were taken during the last 20 minutes of the 120-minute hyperglycemic clamp.
Insulin and C-peptide were measured by radioimmunoassay kits specific for rat/mouse insulin and C-peptide (Linco, St. Charles, MO). Insulin clearance index was calculated as the ratio between C-peptide (nM) and insulin (pM), and the glucose metabolism/plasma insulin (M/I) index of insulin sensitivity (30) was calculated by dividing the glucose infusion rate (Ginf, mmol$kg 21 $min 21 ) by the plasma insulin level (pM) during the last 40 minutes of each step of the clamp in rats and during the last 20 minutes of the clamp in mice. C-peptide levels were taken as an index of absolute insulin secretion, as the insulin secretion rate cannot be calculated in rodents. This is because rat/mouse C-peptide kinetics have not been determined as the species-specific rat/mouse C-peptide is unavailable for injection. b-Cell function in vivo has to be evaluated in the context of insulin sensitivity because the normal b cell increases insulin secretion to compensate for insulin resistance. In normal conditions, the relationship between insulin sensitivity and insulin secretion is hyperbolic (31, 32) ; that is, their product is a constant defined as the disposition index (DI), which is an established index of b-cell function in vivo (31) (32) (33) . The DI was calculated as C-peptide (nM) multiplied by M/I (mmol$kg 
b-cell mass and apoptosis
At the end of the hyperglycemic clamp in mice, the pancreas was removed for determination of b-cell mass and apoptosis as previously described (7).
Studies in vitro
Some evidence in the literature suggests that glucose toxicity in vitro in rodent islets is best demonstrated if control islets are incubated for 48 or 72 hours in higher glucose levels than fasting basal concentrations, and prolonged hyperglycemia is mimicked by higher glucose levels than the 20-mM glucose levels used in our ex vivo study (34) . Therefore, after isolation, rat or mouse islets were incubated at 11 mM or 30 mM glucose for 48 hours. Rat islets were incubated with and without SP (20 mM) (35), whereas for the mouse model, islets of WT or JNK-1-null mice were studied. After the 48-hour incubation, islets were kept at 2.8 mM for 1 hour and then rechallenged with glucose at 6.5 mM and 22 mM for the evaluation of glucose-stimulated insulin secretion (21) . In rat islets, Western blots for c-jun were performed as described for ex vivo studies.
Statistics
Data are means 6 SEM. One-way nonparametric ANOVA for repeated measurements followed by the Tukey test was used to compare treatments. Calculations were performed using SAS (SAS Institute, Cary, NC).
Results
Rat studies
Blood determinations during 48-hour infusions
Baseline blood glucose and plasma insulin were not different among groups. In rats infused for 48 hours with glucose alone (HG) or in combination with the JNK inhibitor SP (HG + SP), glucose levels were elevated to~20 mM (36) .
b-cell function ex vivo and determinations in islets
After a 48-hour infusion, islets were isolated and exposed to glucose in vitro. Insulin secretion at 2.8 mM glucose did not differ among groups. The 48-hour glucose infusion increased insulin secretion at 6.5 mM but impaired insulin secretion at 13 and 22 mM glucose (P , 0.001 vs SAL). Coinfusion of SP did not affect insulin secretion at 6.5 mM glucose but restored insulin secretion at both 13 and 22 mM glucose (Fig. 1A) . SP alone did not have any effect.
The 48-hour hyperglycemia drastically reduced islet insulin content. The addition of SP significantly increased insulin content (~1.5-fold), but this was still profoundly reduced compared with SAL (Fig. 1B) .
To determine whether SP inhibited JNK, phosphorylation of its target c-jun at serine 73 was assessed by Western blots of islet lysates (17) . The 48-hour glucose infusion increased phosphorylation of c-jun, and the effect was prevented by the coinfusion of SP. SP alone had no significant effect. Although total c-jun appeared to be increased by the 48-hour glucose infusion, which would also be in accordance with JNK activation (37), the effect was not significant (Fig. 2B and 2C ). Total and mitochondrial superoxide were increased by hyperglycemia as previously reported (7) and were not decreased by SP ( Fig. 2D and 2E ).
b-cell function in vivo
To investigate whether JNK inhibition prevents glucose-induced b-cell dysfunction in vivo, a two-step hyperglycemic clamp was performed after the 48-hour infusions. Plasma glucose was elevated to 13 mM until 120 minutes, then to 22 mM until 240 minutes, with no difference among groups (Fig. 3A) . In rats that had received the 48-hour glucose infusion (HG), a lower Ginf was necessary to clamp glucose at 22 mM, indicating that the circulating insulin was inadequate to compensate for insulin resistance (P , 0.05 vs SAL). Unexpectedly, coinfusion of the SP with glucose did not improve Ginf at 22 mM glucose (P , 0.001 vs SAL) (Fig. 3B) .
Basal insulin and C-peptide levels (220 minutes to 0 minutes) were higher in the HG and HG + SP groups than SAL (P , 0.001). In response to increasing glucose levels, plasma insulin and C-peptide rose as expected. Previous hyperglycemia (48-hour glucose infusion) elevated plasma insulin levels at both 13 mM (P , 0.001, HG vs SAL) and 22 mM glucose (P , 0.01), as well as C-peptide at 13 mM glucose (P , 0.001). Coinfusion of SP tended to lower plasma insulin but significantly elevated plasma C-peptide levels at 22 mM glucose (P , 0.05, HG + SP vs SAL and HG; Fig. 3C and 3D) .
The 48-hour glucose infusion lowered the C-peptide to insulin ratio, an index of insulin clearance (P , 0.05, HG vs SAL). Coinfusion of SP significantly elevated this index (P , 0.01 vs HG at 13 mM glucose; P , 0.001 vs HG at 22 mM glucose; Fig. 4A ).
The 48-hour glucose infusion also decreased the insulin sensitivity index (M/I index) at both 13 mM and 22 mM glucose. The M/I index was not changed by the coinfusion of SP at both 13 mM and 22 mM glucose (Fig. 4B) .
Although insulin and C-peptide levels were elevated during the clamp in the rats that had received the 48-hour glucose infusion, the DI, which is an index of b-cell function that takes into account the ability of the b cell to compensate for insulin resistance, was lower compared with SAL. SP coinfusion restored the DI (Fig. 4C ), whereas SP alone had no effect.
In a separate set of experiments, the 48-hour infusion of cyclodextrin dissolved in SAL, the vehicle used for SP infusion, had no significant effects compared with SAL infusion alone on any parameters, including the DI in the absence (DI at 22 mM glucose: SAL = 1.49 6 0.23, n = 4; cyclodextrin = 1.77 6 0.12, n = 3; see the "Materials and Methods" section for DI units) or the presence of concomitant 48-hour glucose infusion (DI at 22 mM glucose: SAL = 1.15 6 0.13, n = 4; cyclodextrin = 1.29 6 0.12, n = 4, P , 0.05 for main effect of 48-hour glucose infusion, not significant for main effect of cyclodextrin).
b-cell function in vitro
To confirm that HG and the JNK inhibitor had direct effects on glucose-stimulated insulin secretion in islets, rat islets were exposed for 48 hours to HG in vitro with or without SP. SP prevented the HG-induced decrease in insulin secretion at 22 mM glucose and also partially prevented the HG-induced increase in insulin secretion at 6.5 mM glucose (36) . HG increased phospho-c-jun, an effect prevented by SP. Total c-jun showed a similar pattern to phospho-c-jun, which, however, did not reach significance (36) . Their ratio (not shown) was not different among groups.
Mouse studies
Blood glucose during 96-hour infusions
In both WT and JNK-1-null (KO) mice receiving the 96-hour glucose infusion, blood glucose was elevated tõ 13 mM (36).
b-cell function ex vivo and determinations in islets Insulin secretion at 6.5 mM glucose did not differ among groups. The 96-hour glucose infusion impaired insulin secretion at 22 mM glucose in WT mice. In contrast, islets of JNK-1-null mice infused with glucose had a similar insulin secretion to those infused with SAL (Fig. 5A) . The 96-hour hyperglycemia decreased islet insulin content bỹ 50% in WT mice but not in JNK-1-null mice (Fig. 5B) .
Coinfusion of the JNK inhibitor SP in WT mice also completely prevented the hyperglycemia-induced decrease in insulin secretion and islet insulin content (36) .
Despite the decrease in insulin content, mouse insulin 2 (Ins2) mRNA was not decreased by previous hyperglycemia. It was, however, increased in the KO mice (Fig. 5C ). The same pattern was observed for Pdx-1 mRNA (Fig. 5D ).
b-cell function in vivo
To investigate whether JNK-1-null mice are protected from glucose-induced b-cell dysfunction in vivo, a onestep hyperglycemic clamp was performed after the 96-hour infusion period. Plasma glucose was elevated and maintained at 22 mM for 120 minutes (Fig. 6A) . In 96-hour glucose-infused WT mice, a lower Ginf was needed to clamp glucose at 22 mM (P , 0.01). In contrast, previous glucose infusion did not lower Ginf in JNK-1-null mice (Fig. 6B) .
In both WT and JNK-1-null mice, basal insulin and C-peptide levels tended to be slightly higher after 96-hour glucose than SAL infusion, although the difference was not significant. In WT mice, clamp insulin and C-peptide levels were similar after 96-hour SAL and glucose infusion. In contrast, in JNK-1-null mice, clamp insulin and C-peptide levels were higher after 96-hour glucose than SAL infusion (Fig. 6C and 6D) .
The C-peptide to insulin ratio (index of insulin clearance) was not significantly different among groups (Fig. 7A) . The 96-hour glucose infusion lowered the sensitivity (M/I) index (Fig. 7B) in both WT and JNK-1-null mice. M/I tended to be lower in glucose-infused Figure 2 . Effects of the JNK inhibitor SP on c-jun phosphorylation and content and total and mitochondrial superoxide levels in rat islets exposed to prolonged hyperglycemia in vivo. (A) Representative immunoblots of phosphorylated c-jun, total c-jun, and actin in freshly isolated islets of rats treated as described in Fig. 1 . Each lane represents islet lysates from one animal. (B, C) Quantification of Western blots. The results are expressed as a percentage of SAL 6 SEM (SAL, n = 6; HG, n = 6; HG + SP, n = 6; SP, n = 5). (D) Total and (E) mitochondrial superoxide levels in freshly isolated islets of rats treated as described in Fig. 1 . Twenty islets were measured per number (rat). The results are expressed as a percentage of SAL 6 SEM (SAL, n = 9; HG, n = 10; HG + SP, n = 4; SP, n = 6). Representative fluorescent images stained with hydroethidine and MitoSox are also shown below each graph. WT than JNK-1-null mice, but the difference was not significant. b-Cell function in vivo, as reflected by the DI, was reduced by 96-hour glucose infusion in WT but not in JNK-1-null mice (P , 0.01 vs all; Fig. 7C ).
b-cell mass and apoptosis
We previously found that 48-hour hyperglycemia at 20 mM increased b-cell mass and did not affect apoptosis in rats (7), indicating that 48-hour hyperglycemia at 20 mM is a model of decreased b-cell function and not of decreased b-cell mass. Also, the milder but more prolonged hyperglycemia in mice tended to increase b-cell mass (36) without affecting apoptosis (not shown), which was barely detectable, similar to our findings in rats. There was no significant difference in either b-cell mass or apoptosis between WT and JNK-1-null mice.
b-cell function in vitro
The acute response to glucose was impaired in HGexposed islets of WT mice and partially restored in islets of JNK-1-null mice (36) . Basal insulin secretion had a similar profile to that found in the in vitro studies in rats; however, in mice there were no significant differences among groups (not shown).
Discussion
We have demonstrated using either (i) the JNK inhibitor SP or (ii) JNK-1-null mice that inhibition of JNK protects against glucose-induced b-cell dysfunction, assessed both in vitro and ex vivo in isolated islets and in vivo during hyperglycemic clamps. These findings suggest that the JNK pathway mediates glucose-induced b-cell dysfunction.
In previous studies, prolonged glucose elevation impaired the b-cell secretory response to glucose in vitro (38) (39) (40) and in vivo (41, 42) . Consistent with these findings, we show that prolonged glucose elevation in vitro or hyperglycemia in vivo decreases glucosestimulated insulin secretion in isolated rat or mouse islets. During the hyperglycemic clamp in vivo, absolute insulin and C-peptide were elevated in rats or mice that Figure 3 . Effects of the JNK inhibitor SP on (A) plasma glucose levels, (B) Ginf, (C) plasma insulin levels, and (D) plasma C-peptide levels during a two-step (13 and 22 mM) hyperglycemic clamp performed in rats infused for 48 h as described in Fig. 1 . Data are means 6 SEM (SAL, n = 10; HG, n = 9; HG + SP, n = 9; SP, n = 8). received the 48-hour glucose infusion. However, glucose decreased insulin sensitivity. In vivo, insulin secretion has to be evaluated in the context of insulin resistance. Under conditions of normal glucose tolerance, insulin secretion increases when sensitivity decreases along a hyperbola (i.e., the product of insulin secretion and insulin sensitivity is a constant). This constant, known as the DI, is an established index of b-cell function in vivo (31-33) that we have previously validated in rodents (43) (44) (45) . The DI was decreased following 48-hour glucose elevation in rats, which is consistent with our previous studies in the same model (7, 16) . Similar to our findings in rats, we report that 96 hours of mild hyperglycemia at~13 mM (a less extreme and more feasible model of hyperglycemia in small rodents) impairs b-cell function ex vivo in isolated islets and in vivo in mice. These results are also consistent with our previous studies where 96-hour hyperglycemia at 15 mM impaired insulin secretion in isolated islets of rats (7, 16) .
JNK has been previously implicated in glucoseinduced b-cell dysfunction in in vitro studies in human islets (17) . Furthermore, it has been shown that overexpression of dominant negative JNK in islets preserves insulin gene transcription after transplantation into streptozotocin-diabetic nude mice (18) , suggesting that JNK activation may be involved in b-cell glucotoxicity also in vivo. However, in the diabetic milieu, in addition to hyperglycemia, many other metabolic alterations are present, which can potentially affect b-cell function. The novelty of the present findings is the investigation of the role of JNK in a selective in vivo model of glucose-induced b-cell dysfunction. Although the application of our findings to the more complex abnormalities characteristic of uncontrolled diabetes remains to be validated, it is worth noting that our results are in agreement with the previously reported findings in streptozotocin-induced diabetes (18) .
Using the JNK-specific inhibitor SP, we show that hyperglycemia-induced b-cell dysfunction in rat or mouse islets is prevented. Calculation of the DI demonstrates that the JNK inhibitor prevents hyperglycemiainduced b-cell dysfunction also in vivo. However, despite ameliorating the DI, coinfusion of the JNK inhibitor did not improve Ginf in rats. This is likely due to its concurrent effect to increase insulin clearance (thus ameliorating the secretion of insulin but also increasing its plasma disappearance). It can be argued that in vivo, the improvement in the DI could be secondary to the increase in insulin clearance, which may have stimulated b-cell compensation for insulin resistance. Nevertheless, the data from isolated islets clearly show a direct effect of the JNK inhibitor on the b cell. Furthermore, similar to SP-infused rats, JNK-1-null mice were protected from the hyperglycemia-induced decrease in the DI, and in this model, the improvement in b-cell function resulted in improved Ginf because insulin clearance was not affected by either 96-hour hyperglycemia or JNK-1 deletion. The difference between our findings in mice and rats is likely explained by the milder hyperglycemia in mice, although we cannot exclude effects of the different modality of JNK inhibition (acute with SP vs chronic in JNK-1-null mice), preferential liver vs islet effects of SP, effects related to JNK-2 or JNK-3 (inhibited by SP), and ultimately species specificity (rat vs mouse).
In rats, hyperglycemia in vivo increased basal insulin secretion and the JNK inhibitor did not prevent the effect of glucose, suggesting that this effect is, at least in part, independent of JNK. As previously discussed (7), this effect may be due to induction of glycolytic genes by glucose (46) . The increase in basal insulin secretion was not observed in mice, likely due to milder hyperglycemia in the mouse model.
In vitro, HG also induced basal hypersecretion, albeit not significantly in mice. SP appeared to reduce basal hypersecretion in vitro in both rats and mice, suggesting that, in the in vitro model when islets are not vascularized and under stress, JNK may contribute to glycolytic enzyme stimulation, as previously reported (47) .
As expected, HG induced insulin resistance, but unexpectedly, either pharmacological or genetic inhibition of JNK did not ameliorate the sensitivity index during the hyperglycemic clamp. JNK is mostly implicated in insulin resistance in the liver (5), but during hyperglycemic clamps, sensitivity index is mostly a measure of peripheral rather than hepatic insulin sensitivity because of complete suppression of glucose production by hyperglycemia and endogenous hyperinsulinemia. Because the JNK inhibitor (SP) affected insulin clearance, which is a liver process that shares some molecular mechanisms with hepatic insulin action (48), JNK inhibition, despite having no effect on glucose-induced peripheral insulin resistance, may have improved hepatic insulin resistance. Detection of hepatic insulin resistance would have required the use of a hyperinsulinemic clamp with tracer methodology in a separate set of animals because performing both clamps in the same subject is too invasive for small rodents.
In contrast with its apparent lack of effect on insulin sensitivity, JNK inhibition had profound effects on b-cell function, and our in vitro studies suggest this was a direct effect on islets. Notably, chronic hyperglycemia has been found to also lead to a-cell glucotoxicity, which may raise the question of indirect glucose and JNK effects on b cells via a cells, which could be preserved in the in vitro model. However, a-cell glucotoxicity required 6 days of glucose infusion (49) .
HG may activate JNK in islets via oxidative stress (14) . Our previous study in the same model in rats demonstrates that prolonged hyperglycemia increases superoxide in islets, which impairs b-cell function (7). In the current study, the JNK inhibitor did not affect islet reactive oxygen species (ROS), indicating that JNK activation is either downstream of ROS or in a parallel pathway to oxidative stress.
In addition to oxidative stress, prolonged glucose elevation has been reported to increase ER stress (50) and cytokines (51) (e.g., IL-1b) in b cells, and both have been shown to activate JNK (52, 53) . In our in vivo model in rats, we have shown that ER stress plays a role in glucoseinduced b-cell dysfunction (16); thus, ER stress may have contributed to JNK activation. In vivo, islet JNK activation may be increased by the ER stress induced by the attempted compensation for insulin resistance, which may explain our finding that the effect of JNK inhibition appeared to be greater in vivo and in islets ex vivo than in vitro.
JNK activation has been reported to impair the insulin signaling cascade (15) and thus activate FOXO-1, resulting in decreased expression and nuclear localization of Pdx-1 (54) with consequent reduction in insulin gene transcription. FOXO-1 can also be activated by JNK independent of its effect on insulin signaling (55) . In addition, JNK can decrease insulin gene transcription via c-jun (56) and can decrease insulin translation via the mTOR pathway as a result of impaired insulin signaling (57) . In both rats and mice, islet insulin content was decreased by hyperglycemia, indicating that insulin biosynthesis was unable to cope with increased secretion. The milder decrease in insulin content in mice is in accordance with the milder degree of hyperglycemia as shown by our previous studies in a model of mild hyperglycemia in rats (16) . In our model of severe hyperglycemia in rats, Ins2 mRNA tended to be decreased (7), as previously reported (18) ; however interestingly, in the milder model of the current study in mice, Ins2 and Pdx-1 mRNA were not decreased. This presumably indicates that the decreased insulin content was due to relative failure of insulin transcription to keep up with increased insulin secretory demand and/or that insulin translation was impaired, absolutely or relatively. JNK-1 deficiency increased both Ins2 and Pdx-1 mRNA, suggesting an improvement of the transcriptional response to hyperglycemia that resulted in normalization of the insulin Figure 6 . Effects of genetic deficiency of JNK-1 on (A) plasma glucose levels, (B) Ginf, (C) plasma insulin levels, and (D) plasma C-peptide levels during one-step hyperglycemic clamp in mice treated as described in Fig. 5 . Data are means 6 SEM (WT SAL, n = 7; WT HG, n = 7; KO HG, n = 8; KO SAL, n = 8). *P , 0.05 vs all; **P , 0.01 vs all.
content in the mild hyperglycemia model in mice. In the more severe model of hyperglycemia in rats, JNK inhibition only partially prevented the decrease in insulin content. However, the small improvement in content in rats was likely enough to completely restore secretion, although it cannot be excluded that JNK, in addition to insulin content, affects other processes involved in insulin secretion.
In conclusion, our study demonstrates that inhibition of JNK, using either (i) the JNK inhibitor SP or (ii) JNK-1-null mice, protects against b-cell dysfunction selectively induced by glucose in vitro, ex vivo, and in vivo. Furthermore, this study suggests that JNK inhibitors are of potential interest in the preservation of b-cell function in type 2 diabetes. Figure 7 . Effects of genetic deficiency of JNK-1 on (A) insulin clearance index, (B) sensitivity index, and (C) DI during the one-step hyperglycemic clamp in mice. See the "Materials and Methods" section for calculation of these indices. Data are means 6 SEM (WT SAL, n = 7; WT HG, n = 7; KO HG, n = 8; KO SAL, n = 8). ‡ ‡ P , 0.01 vs WT SAL; ‡ ‡ ‡ P , 0.001 vs WT SAL; **P , 0.01 vs all.
